Wall Street Zen Upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) to “Buy”

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Up 0.9%

NASDAQ:ENTA opened at $13.95 on Friday. The company’s 50 day moving average price is $13.57 and its 200-day moving average price is $13.66. Enanta Pharmaceuticals has a 52 week low of $5.55 and a 52 week high of $17.15. The stock has a market cap of $405.67 million, a price-to-earnings ratio of -5.39 and a beta of 1.01.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. The firm had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -2.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENTA. Janus Henderson Group PLC raised its position in Enanta Pharmaceuticals by 91.6% in the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after acquiring an additional 1,782,745 shares during the period. Commodore Capital LP bought a new position in Enanta Pharmaceuticals in the third quarter worth approximately $9,576,000. Krensavage Asset Management LLC raised its position in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after acquiring an additional 651,946 shares during the period. Farallon Capital Management LLC raised its position in Enanta Pharmaceuticals by 30.6% in the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after acquiring an additional 650,000 shares during the period. Finally, Spruce Street Capital LP raised its position in Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock worth $11,779,000 after acquiring an additional 542,911 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.